# Asthmatx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asthmatx

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.asthmatx.com
- Total disclosed funding: $42M
- Latest round: Series C (Dec 19, 2005)
- Investors on record: 7

## About

Asthmatx is a medical technology company focused on developing innovative therapies for asthma management, utilizing advanced techniques to enhance patient outcomes and treatment efficacy.Founded in 2003 and headquartered in Sunnyvale, US, Asthmatx specializes in asthma therapies. In 2010, the company was acquired by Boston Scientific Corporation for USD 193.5 mn, following a strategic pivot towards broader therapeutic solutions. The firm has participated in 5 deals since inception, with their latest significant transaction occurring on October 26, 2010. The founder, whose previous experiences include entrepreneurship in the healthcare sector, led the company through its early stages until this acquisition.Asthmatx specializes in delivering advanced therapies for asthma management aimed at improving patient outcomes. Their products leverage innovative medical technologies designed specifically for enhancing the efficacy of asthma treatments, thus providing healthcare professionals with effective solutions to manage this condition.The company's revenue stream is primarily generated through innovative therapy solutions designed for asthma management, catering to healthcare systems and professionals. Their business model focuses on strategic partnerships and sales of proprietary technologies, which contribute to a steady revenue flow as healthcare providers adopt these advanced treatments.Asthmatx aims to expand its product line with new asthma therapy devices expected to launch in the coming years. The company is also targeting growth into international markets, particularly in Europe and Asia, by 2015. Proceeds from the acquisition by Boston Scientific Corporation will be allocated towards enhancing research and development initiatives to support these new product launches and geographic expansion.

## Funding rounds

- Series C, Dec 19, 2005, $27M — MedVenture Associates, Vanguard Ventures, Polaris Partners, HBM Partners, Montreux Equity Partners
- Series B, Mar 5, 2004, $16M — MedVenture Associates, Menlo Ventures, Polaris Partners, Montreux Equity Partners, Boston Scientific Ventures

## Investors

- MedVenture Associates (https://capitalatlas.ai/funds/medventure-associates) — Series B, Series C
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series B, Series C
- Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series B
- Vanguard Ventures (https://capitalatlas.ai/funds/vanguard-ventures) — Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C